Zoledronic Acid Injection, Solution
Product Images NDC 63323-966

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Zoledronic Acid (NDC 63323-966). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Fresenius Kabi Usa, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Zoledronic04 (Zoledronic04)

NDC 63323-966-00 is a sterile solution for intravenous infusion. It is a 100mL single-dose vial that should be stored at a temperature between 15-30°C (59-86°F), excluding excursions permitted, as per USP Controlled Room Temperature. The solution contains 5mg/100mL Zoledronic Acid and should not be mixed with alcohol-containing solutions. The pharmacist should dispense the medication with the accompanying coding area to each patient. It is recommended to administer the solution through a separate vented infusion line and not for a time of less than 15 minutes.*

FDA Label Image

Zoledronic05 (Zoledronic05)

This is a package insert for Zoledronic acid, which is a medication used for the treatment of osteoporosis and bone metastasis. It is a sterile solution that is administered through intravenous infusion. Each vial contains 5.33 mg of zoledronic acid monohydrate, equivalent to 5 mg of zoledronic acid and other ingredients. The solution should not be mixed with calcium-containing solutions and should be administered through a separate vented infusion line. The infusion time must not be less than 15 minutes. The solution is stable for 24 hours when refrigerated. The medication guide should be dispensed to each patient.*

FDA Label Image

Zoledronic01 (Zoledronic01)

FDA Label Image

Zoledronic02 (Zoledronic02)

FDA Label Image

Zoledronic03 (Zoledronic03)

This text describes the therapeutic response over time, specifically the normalization of Serum Alkaline Phosphatase (SAF) levels. It indicates that there is data about the change in SAF levels over a period of time, likely due to medical treatment, and the normalization of these levels is being tracked.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.